Summary of Vitamin B2
Primary Information, Benefits, Effects, and Important Facts
Vitamin B2 refers to the molecule known as riboflavin, which is a vitamin because it can produce two cofactors abbreviated as FAD and FMN. Some proteins in the body are dependent on these cofactors to function optimally and dietary riboflavin is the sole provider of FAD and FMN for these enzymes, which are called flavoproteins since FAD and FMN are 'flavins' and work in concert with these proteins.
True deficiencies of riboflavin result in a condition known as ariboflavinosis, which is fairly rare in first world countries but characterized by various ailments of mucuous membranes (mouth and throat) and the skin as well as eye problems. Suboptimal deficiencies are somewhat prevalent although not common aside from a few groups, and for the most part do not result in any major health-threatening conditions.
Groups that would benefit from riboflavin supplementation include adolescent and young adult women, particularly in the UK where riboflavin is not fortified in food to as high a level as in the US and Canada, and the elderly which tend to have less than optimal intakes of riboflavin.
Beyond merely supporting a good riboflavin status, supplementation has a possible benefit for cardiovascular health in a certain population. People who have two copies of a certain gene, known as MTHFR 677TT, have a condition where homocysteine is abnormally elevated due to defects in folate metabolism. These people may experience reductions in blood pressure and homocysteine when riboflavin is supplemented at a low dose. Higher doses of riboflavin (at around 400mg taken in split doses throughout the day) may also have a therapeutic effect for migraines.
Overall, riboflavin is a vitamin which someone could not ingest enough of if their diet is poor, yet a better diet could correct this. Supplementation is never mandatory but is likely prudent for people who are confirmed to be MTHFR 677TT or for anemics on iron repletion therapy (where optimizing riboflavin intake would aid the utility of supplemental iron).
How to Take Vitamin B2
Recommended dosage, active amounts, other details
Riboflavin, for the purpose of maintaining a sufficient riboflavin status in the body, can be supplemented at a relatively low dose of 1-2mg daily to support riboflavin stores in the body. Higher dose (4mg) may increase stores more rapidly but may perform equally over the long term, and these doses are also what should be taken for the purpose of reducing homocysteine concentrations.
For the purpose of reducing migraines, while the optimal dose is not yet confirmed many studies use a total daily dose of 400mg riboflavin divided into various doses throughout the day; riboflavin at these doses (50mg or more) should be taken with food, a dosing modification which does not apply to lower dose supplementation which is fine on an empty stomach.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects vitamin b2 has on your body, and how strong these effects are.
|Grade||Level of Evidence [show legend]|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Homocysteine||Notable||Moderate See all 5 studies|
|Migraine||Notable||Moderate See all 7 studies|
|Blood Pressure||Minor||Very High See all 3 studies|
|Anti-Oxidant Enzyme Profile||-||- See study|
|C-Reactive Protein||-||- See study|
|Ferritin||-||- See study|
|Symptoms of Multiple Sclerosis||-||- See study|
|Uric Acid||-||- See study|
Studies Excluded from Consideration
Confounded with other dietary supplements
Scientific Research on Vitamin B2
Click on any below to expand the corresponding section. Click on to collapse it.
Riboflavin, also called vitamin B-2-, was the second B-complex vitamin to be discovered, with essentiality in humans being shown in 1939.
According to the USDA Food Composition Database, the best sources of dietary riboflavin per 100 grams of food, excluding fortified foods, are:
2 to 5 mg: liver (beef, lamb, chicken, etc.)
1 to 2 mg: kidney, heart, almonds, muscadine grapes
0.5 to 1 mg: goat cheese, game meats, roe and caviar, egg yolk, wheat germ and bran
0.3 to 0.5 mg: red meats and pork, shellfish, fatty fish (mackerel, salmon, trout, etc.), sesame seeds and tahini, mushrooms
Riboflavin is relatively heat-stable, with a melting point of 278-282°C and able to withstand heating processes like hot air convection, infrared, high-pressure steam, and microwave during cooking, as well as milk pasteurization. When dissolved in water, heating the riboflavin solution for 40 minutes at 100, 120 and 150 °C destroys 4, 7, and 28% of the riboflavin, respectively.
While eventually being degraded in response to heat, riboflavin is relatively heat resistant and should not significantly degrade under most practical situations (cooking foods with riboflavin in them).
Although riboflavin is somewhat heat-resistant, it is highly sensitive to light. Aqueous riboflavin is strongly absorbs and is photodegraded by various ultraviolet and blue wavelengths (223, 267, 373, and 444 nm). Photodegradation also occurs when riboflavin is in powdered form or tablets, with the powder turning greenish depending on humidity and moisture.
There may be slightly more photostability when riboflavin is in a liposome, especially when in the liposome alongside something else that can absorb light and degrade in its place, but the degradation still occurs in a linear fashion when light is present.
Riboflavin is unstable in light both as a solid and even more so when in aqueous solution. Riboflavin should be stored in a dry, dark place.
Riboflavin is an essential vitamin used to produce the two flavocoenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are involved primarily in reduction-oxidation (redox) reactions in metabolism, with most flavoproteins using FAD (84%) over FMN (16%).
In energy metabolism, FMN is involved in complex I of the respiratory chain, while FAD is involved in complex II of the respiratory chain, amino acid catabolism, fatty acid beta-oxidation, and proper function of the TCA cycle.
FAD also plays an important role in the body’s antioxidant system, being a cofactor for glutathione reductase. It serves as the link between energy metabolism and the antioxidant system as electrons move from NADPH to FAD to glutathione.
Four riboflavin-dependent enzymes are involved in folate metabolism, vitamin B12 metabolism, and the methionine-homocysteine cycle: methylenetetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR), dimethylglycine dehydrogenase (DMGDH), and sarcosine dehydrogenase (SARDH).
Other biosynthetic roles of riboflavin include:
The biosynthesis of heme requires the FAD-dependent protoporphyrinogen IX oxidase (PPOX).
Synthesis of niacin from tryptophan requires FAD for kynurenine 3-monooxygenase (
The biosynthesis of coenzyme A from pantothenic acid requires the FMN-dependent 4-phosphopantothenoylcysteine decarboxylase (PPCDC).
The biosynthesis of cholesterol depends on two FAD-dependent enzymes: squalene monooxygenase (SQLE) and 3β-hydroxysterol 24-reductase (DHCR24).
Protein folding in the endoplasmic reticulum is FAD-dependent.
Riboflavin is used to create the coenzymes FAD and FMN, which are used by many enzymes in redox reactions to facilitate energy metabolism, the antioxidant system, and biosynthesis.
Clinical riboflavin deficiency (ariboflavinosis) is rare in the developed world, except in pockets of low socioeconomic status, and high in the developing world. The signs of ariboflavinosis are sore throat; hyperemia and edema of the throat and mouth; cheilosis; angular stomatitis; glossitis; seborrheic dermatitis; and normochromic, normocytic anemia associated with pure erythrocyte cytoplasia of the bone marrow.
The recommended daily allowance (RDA, or the amount needed to meet the nutritional needs of 97–98% of healthy people in a given demographic) for those 19 years and older is 1.3 mg/day for men and 1.1 mg/day for women. The RDA increases to 1.4 mg/day for pregnant women, and to 1.6 mg/day for lactating women.
Importantly, the value for lactating women assumed that women provide 0.35 mg/L of riboflavin in breast milk. At least one study of healthy women reported that daily secretion of riboflavin in breast milk was 0.010–0.55 mg and strongly correlated with dietary riboflavin intake from diet and supplements over the range of 1–8 mg/d. Mothers deficient in riboflavin may deliver only around half of a child's requirements through her breast milk.
In the US, average riboflavin intake from food alone is 1.9–2.3 mg/d and only 2.9% consume less than the estimated average requirement (EAR) of 1.1 mg/d for men and 0.9 mg/d for women. When dietary supplements are considered, average intake levels are 2.0–5.7 mg/d and just 2.4% of Americans consume less than the EAR.
Adults require 1–2 mg of riboflavin per day. In the US, average intakes are above this and deficiency is rare.
Fourteen biomarkers of riboflavin status have been identified, but most have been investigated in only 1-2 studies. The gold-standard is the erythrocyte glutathione reductase activation coefficient (EGRAC), which represents the ratio of FAD-stimulated to unstimulated enzyme activity.
EGRAC values close to 1.0 indicate glutathione reductase is saturated with FAD, while higher values indicate increasing deficiency of FAD and riboflavin. Sufficient riboflavin status is suggested to correspond to an EGRAC of 1.0 to 1.2, insufficient status to an EGRAC of 1.2 to 1.4, and deficiency to an EGRAC >1.4.
People who are heterozygous for glucose-6-phosphate dehydrogenase deficiency may have low EGRAC status independent of riboflavin, confounding the measurement. EGRAC is therefore not an appropriate biomarker to measure riboflavin status in these people.
Although full-blown deficiency of riboflavin is rare in developed worlds, suboptimal status may be widespread. In elderly adults who consumed an average of 1.6 mg/d of riboflavin, 45% had suboptimal riboflavin status that was corrected with an additional 1.6 mg/d of supplemental riboflavin; the EGRAC was improved more so with 25 mg/d. Another study involved women who were deficient in riboflavin despite consuming an average of 1.14–2.3 mg/d.
Riboflavin status is measured by the EGRAC ratio, where less 1.0 to 1.2 is considered optimal (suggesting saturation of riboflavin in tissues) and higher values suggest increasing riboflavin deficiency. A significant portion of the developed world appear to have suboptimal riboflavin status despite consuming the RDA for riboflavin.
More than 90% of dietary riboflavin is in the form of FAD or FMN; the remaining 10% is comprised of the free form and glycosides or esters. The most common forms of riboflavin available in supplements are riboflavin and riboflavin 5'-monophosphate.
Dietary riboflavin is mostly FAD or FMN, and supplements supply either free riboflavin or riboflavin 5'-monophosphate.
Dietary sources of riboflavin tend to be in the form of its cofactors, flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), which are bound to proteins in the food. These cofactors are liberated from food by the acidic environment in the stomach releasing free FMN and FAD. FMN and FAD are hydrolyzed into free riboflavin by phosphatases in the intestines, a requirement for absorption.
Riboflavin in food exists in a protein-bound state. The acidic environment of the stomach dissociates these riboflavin-protein complexes, releasing free riboflavin for absorption in the intestines.
In the small intestine, riboflavin is taken up by its transporters designated RFVTs, including RFVT1 (SLC52A1), RFVT2 (SLC52A2) and RFVT3 (SLC52A3), which are all expressed in the apical membranes of both the jejunum and ileum.
Bioavailability of riboflavin (as orally administred FMN) is better when taken with food than when taken in isolation at doses of 10-30mg. No differences have been found at lower doses,however, with 5mg riboflavin having a bioavailability of around 58% with or without food. Food sources seem similar in riboflavin absorption (400μg riboflavin), with spinach and milk both having 60-67% riboflavin bioavailability.
Higher doses of riboflavin have been shown to have lower bioavailabilities of 14.5% (150mg) and 8.3% (300mg) as assessed by urinary recovery of riboflavin. This is consistent with the threshold for intestinal riboflavin saturation, which seems to occur around the 27-50mg range. It should be noted that riboflavin can be absorbed passively through intestinal epithelial cells, suggesting that doses in excess of the threshold for transporter saturation can still be absorbed.
The small intestines mediate most of the absorption of riboflavin, where it appears to be a simple absorption process. Low supplemental doses (5mg) can be taken with or without food, while higher doses are better absorbed with food.
Some riboflavin uptake can occur in the colon (large intestine) also via a saturable transporter. Although colonic transporters seem to have less maximal capacity than those in the small intestine, they seem to be equally potent with low (0.1µM) concentrations of riboflavin. These transporters may have a role in taking up the riboflavin produced by intestinal bacteria, with Lactobacillus and potentially bifidobacteria being able to produce riboflavin (ex vivo in food products).
The colon is capable of absorbing some riboflavin at a lesser capacity than the small intestines, which may faciliate the absorption of riboflavin produced by intestinal bacteria. The overall contribution of intestinal bacteria to riboflavin status is not currently known.
Renal (kidney) elimination of riboflavin is mediated by the same transporters expressed in the intestines (RFVTs) which mediate resorption back into the blood. Expression of these transporters can be reduced by chronic administration of ethanol, reducing resorption and resulting in increased elimination.
One study assessing riboflavin repletion found that supplementation was able to increase riboflavin stores in the body after six weeks (1.6mg daily) with higher doses (2-4mg) being able to increase stores at four weeks, with levels remaining elevated over eight weeks. After supplementation is ceased, riboflavin stores have been shown to return to baseline after six months.
Although the cause of migraine headaches is unknown, a large number of studies have noted impaired mitochondrial function in patients with migraines. Defects in both brain and mitochondrial energy metabolism have been associated with complicated migraine, migraine with aura, and migraine without aura. As a precursor to FMN and FAD, riboflavin is an essential component of mitochondrial ATP production. Thus, riboflavin has been investigated as a treatment for migraines, in hopes that it may augment the impaired mitochondrial function that is thought to be the cause of headaches. Riboflavin treatment has shown some efficacy in this regard, reducing the frequency of migraines and encephalopathy in patients with MELAS (mitochondrial encephalomyopathy and stroke-like episodes).
Migraine headaches are associated with impaired mitochondrial metabolism. Because riboflavin is a source of FAD and FMN cofactors important for mitochondrial ATP production, it has been investigated for the treatment of migraine headaches.
In subjects diagnosed with migraine (with or without aura) with a headache frequency of 2-8 headaches a month who were given a high dose of riboflavin (400mg) over three months, there was a reduction in headache frequency and duration without any influence on headache intensity. The therapeutic effect persisted for three months after supplement cessation. Similar benefits of 400mg riboflavin over placebo have been noted elsewhere, with 59-68.4% of patients reporting a greater than 50% reduction in migraine frequency. One study using 25mg riboflavin as the 'placebo' treatment also noted that 44% of participants reported more than a 50% reduction in migraine frequency. It is uncertain, despite the aforementioned study, if lower doses are equally effective as other studies using 200mg and 50mg have failed to find benefits with riboflavin treatment. Due to the fact that some studies have failed to note benefits with riboflavin treatment, it has been suggested that there may be a mitochondrial genetic component to riboflavin therapeutic response.
The ability of riboflavin to reduce migraine intensity is either not present, as noted in one study, or relatively modest, with a 21% reduction in intensity noted in another study. Moreover, other work comparing 25mg riboflavin to 400mg riboflavin alongside other migraine treatments (300mg magnesium and 100mg feverfew) failed to note any differences in migraine intensity between treatments.
A few studies have found that riboflavin is effective for reducing migraine frequency and duration. The effect of riboflavin on migraine intensity has been inconsistent, with at least one study noting a reduction in headache intensity while others have failed to show any effect. Most studies showing efficacy used 400mg riboflavin daily. The idea that lower (25mg) doses are equally effective is plausible, but requires further testing.
Supplementation of riboflavin (2mg or 4mg) in women who were somewhat deficient in riboflavin (as assessed by EGRAC) over the course of 8 weeks was able to improve hemoglobin status of the blood, with the degree of improvement correlating with the extent of underlying deficiency. This has also been noted elsewhere with 2mg riboflavin (amongst other nutraceuticals) over 12 weeks, which also slightly improved hemoglobin content in moderately deficient subjects. Riboflavin taken alongside 5mg Vitamin C has shown similar positive effects in riboflavin- deficient young adults. Riboflavin is also included in combination supplements to address iron deficiency in third world countries at doses around 2mg; while absorption of iron is unaffected by riboflavin, being riboflavin-deficient seems to be associated with less iron utilization.
One study has noted that removal of supplementation caused the beneficial changes in hemoglobin and hematocrit counts to reverse in adults whose diet was deficient in riboflavin.
In elderly subjects who appeared to have suboptimal riboflavin status, supplementation of riboflavin (10mg) for four weeks did not appear to significantly alter ferritin concentrations. Also, neither iron absorption rates nor ferritin levels changed in younger women whose hemoglobin levels increased due to replenishing riboflavin stores via supplementation.
It seems that proper hemoglobin levels require adequate riboflavin intake (amongst other red blood cell nutrients such as iron). There is no evidence to suggest that supplementing higher than normal riboflavin can enhance red blood cell function, but fixing a riboflavin deficiency can increase hemoglobin levels.
An enzyme known as methylenetetrahydrofolate reductase (MTHFR) which reduces 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, is needed to convert homocysteine (a risk factor for coronary heart disease, into L-methionine. The activity of the MTHFR enzyme is generally thought to be protective against coronary heart disease, since reduced activity predicts coronary heart disease, particularly in those deficient in folic acid (from which 5,10-methylenetetrahydrofolate is made).
One specific gene mutation which reduces activity of the enzyme is MTHFR 677C->T, which causes alanine 222 in the MTHFR protein to be substituted with valine, resulting in reduced biding of the MTHFR enzyme to its riboflavin cofactor (flavin adenine dinucleotide or FAD). This genetic polymorphism has been identified as a risk factor for coronary heart disease. Rates of being homozygous for this polymorphism (known as having the MTHFR 677TT genotype, since each of the two copies of the gene are T's instead of C's) tend to vary between 3-32% across the world. This polymorphism does not raise the risk of all populations equally, however; the risk for coronary heart disease which this mutation confers is higher in European countries relative to North America. This difference has been hypothesized to be due to the fact that riboflavin has been fortified in foods in North America for several decades.
The action of the enzyme MTHFR plays a role in reducing homocysteine levels, an intermediate in metabolism that is a risk factor for coronary heart disease. Mutations that decrease the activity of MTHFR thus increase the risk for heart disease. FAD (which is made in part from riboflavin) is a cofactor for this enzyme.
Supplementation of riboflavin (1.6mg) for 12 weeks in subjects positive for the MTHFR 677C->T polymorphism reduced homocysteine levels in only in subjects who were MTHFR 677TT homozygous, where homocysteine levels decreased by 22% in those with normal riboflavin status. Larger decreases (in upwards of 40%) were noted in homozygous individuals with lower riboflavin status, suggesting that riboflavin intake affects homocysteine levels in these individuals.
In a large assessment of MTHFR mutations, it was found that overall subjects who had the MTHFR 677T allele had higher homocysteine concentrations, but this increase was not found in individuals whose riboflavin status was considered optimal (only in those with lower riboflavin status). Riboflavin status does not appear to influence homocysteine in the context of another mutation known as MTRR 524T, a flavoprotein that helps refresh methionine synthase, the enzyme that catalyzes the formation of methionine from homocysteine.
Subjects who are homozygous for the MTHFR 677C->7 polymorphism (aka. MTHFR 677TT) appear to experience greater reductions in homocysteine in response to a relatively low supplemental doses of riboflavin, which is thought to then reduce the risk of coronary heart disease.
Administration of riboflavin at a dose of 1.6mg over 12 weeks failed to significantly reduce total homocysteine concentrations in healthy elderly subjects with suboptimal riboflavin status (11.1% of whom had the MTHFR 677TT genotype). Although the next phase of the study introducing 400µg folic acid alongside the riboflavin effectively reduced homocysteine levels, riboflavin did not appear to confer additional benefits over folic acid alone. This was investigated since it was previously noted that after folic acid-induced reductions in homocysteine, Vitamin B12 has a more prominent homocysteine-reducing role and Vitamin B6 is also effective after folic acid (although working via a different pathway, reducing homocysteine concentrations by converting it into L-cysteine via cystathionine β-synthase).
One other study using 10mg riboflavin for a month in elderly subjects with low riboflavin status did find a minor reduction in homocysteine concentrations in serum, although this was not correlated to MTHFR genotype.
Studies on the effect of riboflavin supplementation on homocysteine levels in elderly populations have yielded mixed results. One study assessing the ability of riboflavin to decrease homocysteine in an elderly population who are predominantly not MTHFR 677TT did not find any benefits of supplementation, even though they had a suboptimal riboflavin status. Another study found the riboflavin caused mild decreases in homocysteine levels, although the MTHFR genotype in the study population was not assessed.
In subjects on medication who had hypertension alongside the MTHFR 677TT genotype, supplementation of riboflavin at 1.6mg daily for 16 weeks was able to promote an additional reduction of blood pressure of 5.6+/-2.6mmHg systolic with no change in diastolic blood pressure. This dose of riboflavin has elsewhere shown benefits where MTHFR 677TT patients with premature cardiovascular disease were less responsive to medication but normalized (relative to hypertensive subjects without the homogyzous mutation) with riboflavin. The efficacy of riboflavin supplementation for MTHFR 677TT individuals was further confirmed in the same cohort four years later, despite increases in the number of other blood pressure medications taken; systolic blood pressure in these subjects decreased by -9.2+/-12.8mmHg with a decrease in diastolic blood pressure of -6.0+/-9.9mmHg.
In nickel-allergic subjects who were irradiated by UVA (385nm) and UVB (300nm) rays under experimental conditions, application of a topical cream containing riboflavin to the site a day prior and again 30 minutes prior to radiation appeared to preserve nickel-induced reddening of the skin, suggesting protection against UV-induced immunosuppression. Such skin-level immunosuppression can lead to skin cancer.
Riboflavin is taken up into pancreatic β-cells via transporters similar to those present in the intestines (RFVT1-3, with RFVT3 being more prominent in human pancreatic cells). Uptake occurs at a similar rate when the concentration is held at 14nM (Km of 0.17+/-0.02μM), with higher concentrations (10µM) thought to also confer a localized antiinflammatory effect in response to inflammatory cytokines (IL-1β, IFN-γ, and TNF-α).
Riboflavin is a component of the retina where it plays roles in aiding function of the photoreceptors in the retina and structurally protecting the surface; higher dietary intakes seem to be associated with reduced formation of nuclear cataracts. Deficiencies of riboflavin, amongst other effects, tend to result in ocular disorders due to damage to the ocular surface.
While riboflavin concentrations in the retina are responsive to the diet, this only occurs up until 3mg/kg in the rat (riboflavin per kilogram of feed) and rabbit as higher feed concentrations do not further increase retinal riboflavin concentration despite increases in serum levels. This may be related to the transporter that mediates riboflavin uptake in the retina, a sodium-independent transporter that appears to be saturated at a concentration of riboflavin between 8nM and 1µM (apparent KM of 80+/-14nM).
Riboflavin has a role in the eyes where it aids in photoreceptors (receptors that respond to color) and structurally protects the eyes.
In patients with glaucoma, supplementation of riboflavin (0.8mg) alongside other nutraceutucals including forskolin (from coleus forskohlii) at 15mg, rutin at 200mg, and thiamin at 0.7mg over the course of one month appeared to reduce ocular surface damage as assessed by ocular discomfort (ocular surface disease index) as well as leading to improvments as assessed by three ocular tests (OPI, FBUT, and Schirmer test 1).
Dietary intake of riboflavin as assessed by food frequency questionnaire (FFQ) in older women appears to be inversely associated with colorectal cancer incidence, with the highest quartile of intake (greater than 3.97mg) having a reduced risk (HR 0.75; 95% CI of 0.62-0.92) when compared to the lowest quartile of total intake (less than 1.8mg).
Supplementation of 10mg riboflavin daily over the course of six months in subjects with multiple sclerosis failed to lessen the disease severity as assessed by the Expanded Disability Status Scale (EDSS) when compared to placebo as both groups benefitted. This study failed to find an influence on serum homocysteine concentrations or antioxidant activity (glutathione reductase) in red blood cells.
Friedreich's ataxia (FRDA) is a genetic disease associated with a mitochondrial mutation that reduces production of a protein called frataxin, increasing iron-mediated oxidative stress which ultimately leads to degeneration of nerve tissue in the spine. Riboflavin is thought to have a role based on studies in S. cerevisiae and C. elegans (fraxatin deficiency models) where the cofactors improved cellular growth and rescued the phenotype resulting from frataxin deficiency.
One preliminary trial using deferiprone (an iron chelator which may have a role in treating FRDA) with added idebenone (10-20mg/kg) and riboflavin (10-15mg/kg) over the course of numerous months found a possible slowing of disease progression which requires future studies to verify due to the open-label, uncontrolled nature of the study, along with a very high dropout rate. These two nutraceuticals have been used in conjunction with darbepoetin alfa (a synthetic form of erythropoietin which may increase frataxin expression) previously for possible benefits in another open-label trial.
The absorption of riboflavin from the intestines is influenced by chronic alcohol intake in the rat, as a high alcohol intake for four weeks (36% of calories coming from ethanol) can reduce the expression of riboflavin transporters RFVT1-3. When tested ex vivo, riboflavin transport appeared to be approximately halved both for intestinal uptake and renal resorption which also saw a decrease in RFVTs.
Alcohol exposure seems to reduce the capacity of the intestines to take up riboflavin into the body, resulting in chronic alcoholics being riboflavin-deficient.
- Nebbioso M1, et al. Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial. Eur Rev Med Pharmacol Sci. (2013)
- Northrop-Clewes CA, Thurnham DI. The discovery and characterization of riboflavin. Ann Nutr Metab. (2012)
- Sheraz MA, et al. Photo, thermal and chemical degradation of riboflavin. Beilstein J Org Chem. (2014)
- Astanov S, et al. Spectroscopic study of photo and thermal destruction of riboflavin. J Mol Struct. (2014)
- Sue-Chu M, Kristensen S, Tønnesen HH. Influence of lag-time between light exposure and color evaluation of riboflavin in the solid state. Pharmazie. (2008)
- Sue-Chu M, Kristensen S, Tønnesen HH. Photoinduced color changes in two different qualities of riboflavin in the solid state and in various tablet formulations photoreactivity of biologically active compounds. XX. Pharmazie. (2009)
- Habib MJ, Asker AF. Photostabilization of riboflavin by incorporation into liposomes. J Parenter Sci Technol. (1991)
- Loukas YL. A Plackett-Burnam screening design directs the efficient formulation of multicomponent DRV liposomes. J Pharm Biomed Anal. (2001)
- Lienhart WD, Gudipati V, Macheroux P. The human flavoproteome. Arch Biochem Biophys. (2013)
- McCormick DB. Two interconnected B vitamins: riboflavin and pyridoxine. Physiol Rev. (1989)
- Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol. (2004)
- Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline.
- Kodentsova VM, Vrzhesinskaya OA. Evaluation of the vitamin status in nursing women by vitamin content in breast milk. Bull Exp Biol Med. (2006)
- Allen LH. B vitamins in breast milk: relative importance of maternal status and intake, and effects on infant status and function. Adv Nutr. (2012)
- Blumberg JB, et al. Contribution of Dietary Supplements to Nutritional Adequacy by Socioeconomic Subgroups in Adults of the United States. Nutrients. (2017)
- Hoey L, McNulty H, Strain JJ. Studies of biomarker responses to intervention with riboflavin: a systematic review. Am J Clin Nutr. (2009)
- Prentice AM, et al. The influence of G-6-PD activity on the response of erythrocyte glutathione reductase to riboflavin deficiency. Int J Vitam Nutr Res. (1981)
- Madigan SM, et al. Riboflavin and vitamin B-6 intakes and status and biochemical response to riboflavin supplementation in free-living elderly people. Am J Clin Nutr. (1998)
- Powers HJ, et al. Correcting a marginal riboflavin deficiency improves hematologic status in young women in the United Kingdom (RIBOFEM). Am J Clin Nutr. (2011)
- McKinley MC, et al. Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. Eur J Clin Nutr. (2002)
- Bailey AL, et al. Relationships between micronutrient intake and biochemical indicators of nutrient adequacy in a "free-living' elderly UK population. Br J Nutr. (1997)
- Gariballa S, Forster S, Powers H. Riboflavin status in acutely ill patients and response to dietary supplements. JPEN J Parenter Enteral Nutr. (2009)
- Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline.
- Merrill AH Jr, et al. Formation and mode of action of flavoproteins. Annu Rev Nutr. (1981)
- Akiyama T, Selhub J, Rosenberg IH. FMN phosphatase and FAD pyrophosphatase in rat intestinal brush borders: role in intestinal absorption of dietary riboflavin. J Nutr. (1982)
- Daniel H, Binninger E, Rehner G. Hydrolysis of FMN and FAD by alkaline phosphatase of the intestinal brush-border membrane. Int J Vitam Nutr Res. (1983)
- Yonezawa A1, Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol Aspects Med. (2013)
- Sabui S1, Ghosal A1, Said HM2. Identification and characterization of 5'-flanking region of the human riboflavin transporter 1 gene (SLC52A1). Gene. (2014)
- Yao Y1, et al. Involvement of riboflavin transporter RFVT2/Slc52a2 in hepatic homeostasis of riboflavin in mice. Eur J Pharmacol. (2013)
- Ghosal A1, Sabui S1, Said HM2. Identification and characterization of the minimal 5'-regulatory region of the human riboflavin transporter -3 (SLC52A3) in intestinal epithelial cells. Am J Physiol Cell Physiol. (2014)
- Yoshimatsu H1, et al. Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption. Am J Physiol Gastrointest Liver Physiol. (2014)
- Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin-5'-phosphate in man. J Pharm Sci. (1967)
- Dainty JR1, et al. Quantification of the bioavailability of riboflavin from foods by use of stable-isotope labels and kinetic modeling. Am J Clin Nutr. (2007)
- Zempleni J1, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr. (1996)
- Zielińska-Dawidziak M1, et al. Transport of high concentration of thiamin, riboflavin and pyridoxine across intestinal epithelial cells Caco-2. J Nutr Sci Vitaminol (Tokyo). (2008)
- Yuasa H1, et al. Carrier-mediated transport of riboflavin in the rat colon. Biopharm Drug Dispos. (2000)
- Tomei S1, et al. Transport functions of riboflavin carriers in the rat small intestine and colon: site difference and effects of tricyclic-type drugs. Drug Deliv. (2001)
- IINUMA S. Synthesis of riboflavin by intestinal bacteria. J Vitaminol (Kyoto). (1955)
- Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev. (1997)
- LeBlanc JG1, et al. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. (2013)
- Subramanian VS1, et al. Chronic alcohol feeding inhibits physiological and molecular parameters of intestinal and renal riboflavin transport. Am J Physiol Cell Physiol. (2013)
- Colombo B1, Saraceno L, Comi G. Riboflavin and migraine: the bridge over troubled mitochondria. Neurol Sci. (2014)
- Barbiroli B1, et al. Complicated migraine studied by phosphorus magnetic resonance spectroscopy. Cephalalgia. (1990)
- Sacquegna T1, et al. Brain energy metabolism studied by 31P-MR spectroscopy in a case of migraine with prolonged aura. Acta Neurol Scand. (1992)
- Welch KM1, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology. (1989)
- Barbiroli B1, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology. (1992)
- Montagna P1, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology. (1994)
- Penn AM1, et al. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology. (1992)
- Boehnke C1, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. (2004)
- Schoenen J1, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. (1998)
- Condò M1, et al. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. (2009)
- Di Lorenzo C1, et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology. (2009)
- Maizels M1, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. (2004)
- MacLennan SC1, et al. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. (2008)
- Bruijn J1, et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. (2010)
- Buzina R, et al. Nutritional status and physical working capacity. Hum Nutr Clin Nutr. (1982)
- Ajayi OA1, Okike OC, Yusuf Y. Haematological response to supplements of riboflavin and ascorbic acid in Nigerian young adults. Eur J Haematol. (1990)
- Powers HJ, et al. The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. Hum Nutr Clin Nutr. (1983)
- Powers HJ, Bates CJ, Lamb WH. Haematological response to supplements of iron and riboflavin to pregnant and lactating women in rural Gambia. Hum Nutr Clin Nutr. (1985)
- Fairweather-Tait SJ1, et al. Riboflavin deficiency and iron absorption in adult Gambian men. Ann Nutr Metab. (1992)
- Tavares NR1, Moreira PA, Amaral TF. Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly. J Nutr Health Aging. (2009)
- Humphrey LL1, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. (2008)
- Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. (2007)
- Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. (1990)
- Frosst P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. (1995)
- Jacques PF1, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. (1996)
- Yamada K1, et al. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A. (2001)
- Varga EA1, et al. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation. (2005)
- Klerk M1, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. (2002)
- Wilcken B, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. (2003)
- McNulty H1, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation. (2006)
- García-Minguillán CJ1, et al. Riboflavin status modifies the effects of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms on homocysteine. Genes Nutr. (2014)
- Quinlivan EP, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet. (2002)
- McKinley MC1, et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr. (2001)
- Jhee KH1, Kruger WD. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal. (2005)
- Wilson CP1, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. (2013)
- Horigan G1, et al. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR. J Hypertens. (2010)
- Wilson CP1, et al. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. (2012)
- Damian DL1, Matthews YJ, Halliday GM. Topical riboflavin attenuates ultraviolet B- and ultraviolet A-induced immunosuppression in humans. Photodermatol Photoimmunol Photomed. (2010)
- Halliday GM1. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res. (2005)
- Said HM. Recent advances in transport of water-soluble vitamins in organs of the digestive system: a focus on the colon and the pancreas. Am J Physiol Gastrointest Liver Physiol. (2013)
- Ghosal A1, Said HM. Mechanism and regulation of vitamin B2 (riboflavin) uptake by mouse and human pancreatic β-cells/islets: physiological and molecular aspects. Am J Physiol Gastrointest Liver Physiol. (2012)
- Cobianchi L1, et al. Riboflavin inhibits IL-6 expression and p38 activation in islet cells. Cell Transplant. (2008)
- Batey DW1, Eckhert CD. Identification of FAD, FMN, and riboflavin in the retina by microextraction and high-performance liquid chromatography. Anal Biochem. (1990)
- Miyamoto Y1, Sancar A. Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. Proc Natl Acad Sci U S A. (1998)
- Takami Y1, Gong H, Amemiya T. Riboflavin deficiency induces ocular surface damage. Ophthalmic Res. (2004)
- Cumming RG1, Mitchell P, Smith W. Diet and cataract: the Blue Mountains Eye Study. Ophthalmology. (2000)
- Batey DW1, Daneshgar KK, Eckhert CD. Flavin levels in the rat retina. Exp Eye Res. (1992)
- Batey DW1, Eckhert CD. Analysis of flavins in ocular tissues of the rabbit. Invest Ophthalmol Vis Sci. (1991)
- Said HM1, Wang S, Ma TY. Mechanism of riboflavin uptake by cultured human retinal pigment epithelial ARPE-19 cells: possible regulation by an intracellular Ca2+-calmodulin-mediated pathway. J Physiol. (2005)
- Zschäbitz S1, et al. B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort. Am J Clin Nutr. (2013)
- Naghashpour M1, et al. Riboflavin Supplementation to Patients with Multiple Sclerosis does not Improve Disability Status nor is Riboflavin Supplementation Correlated to Homocysteine. Int J Vitam Nutr Res. (2013)
- Campuzano V1, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. (1996)
- Cossée M1, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. (1999)
- Gonzalez-Cabo P1, Ros S, Palau F. Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency. PLoS One. (2010)
- Boddaert N1, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. (2007)
- Pandolfo M1, Hausmann L. Deferiprone for the treatment of Friedreich's ataxia. J Neurochem. (2013)
- Arpa J1, et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial. Acta Neurol Scand. (2014)
- Sturm B1, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. (2005)
- Arpa J1, et al. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial. Cerebellum. (2013)
- Neville JN, et al. Nutritional status of alcoholics. Am J Clin Nutr. (1968)
- Leevy CM, Baker H. Vitamins and alcoholism. Introduction. Am J Clin Nutr. (1968)
- Majumdar SK, Shaw GK, Thomson AD. Vitamin utilization status in chronic alcoholics. Int J Vitam Nutr Res. (1981)
- FENNELLY J, et al. PERIPHERAL NEUROPATHY OF THE ALCOHOLIC: I, AETIOLOGICAL ROLE OF ANEURIN AND OTHER B-COMPLEX VITAMINS. Br Med J. (1964)